Damien is a molecular microbiologists with 15 years experience in both academia and industry. Prior to founding Maiden Therapeutics, he was an Entrepreneur-in-Residence within
a Singaporean Venture Capital firm providing domain expertise in microbiology. In Singapore, Damien’s research has been focused on microbial communities, biofilm, and pathogenesis primarily at SCELSE NTU.
Damien received his training in Dublin, Ireland (Ph.D. Molecular Biology, Biotechnology Dept. Dublin City University), where he continued to a lecturing position and worked on
Academic-Industrial projects with Bristol Myers Squibb leading to a university spin-out company
As CEO of Maiden Therapeutics, Damien believes that patients unmet medical needs should be at the heart of the drug discovery platform.